Market Shifts Powering the Growth of Sterile Injectable Manufacturing

Sponsored by Simtra BioPharma Solutions

The sterile injectable contract manufacturing market is undergoing rapid transformation, driven by the dual demands of large-scale biologics and small-batch, targeted therapies. In this video, Franco Negron of Simtra BioPharma Solutions explores the trends shaping the industry and describes how leading CDMOs are expanding capacity, strengthening global redundancy, and investing in talent to meet evolving customer needs.

Negron elaborates on how development and pre-commercial services play a pivotal role in accelerating time to market—ensuring products are designed with the end in mind and ready for smooth scale-up from lab to launch. He also highlights the importance of strategic partnerships and supplier networks that help emerging and established biopharma companies access integrated, end-to-end manufacturing solutions.

From infrastructure investment to operational readiness and collaboration, Negron offers insights into how the sterile injectable manufacturing sector is building resilience and agility for the future of biologics and advanced therapeutics.